How PMDA Assesses Data Reliability: A Practical Checklist for Clinics

Japan’s Pharmaceuticals and Medical Devices Agency checks whether data submitted for drug and regenerative medicine product reviews have been collected and prepared in accordance with applicable reliability standards, including GLP, GCP, and GPSP.

Why this matters to clinics

Clinics involved in clinical studies, post-marketing work, or data generation may become part of the evidence chain reviewed by regulators. The practical issue is therefore not only the final dataset, but also whether the underlying records, procedures, and responsibilities can be traced.

Core operational checks

Consent records should be current and version-controlled. Source data should be identifiable. Standard operating procedures should match actual practice. Storage locations, access rights, and correction histories should be clear enough that another person can reconstruct what happened.

Prepare for questions before they arrive

A short internal mock review can expose gaps early. Staff should know who is responsible for each record, where documents are stored, and how discrepancies are corrected. The goal is not to create paperwork for its own sake, but to ensure that the data can be trusted.

Real-world data

PMDA also supports initiatives related to the reliable use of real-world data. The same principle applies: data are more useful when their origin, collection method, and governance can be explained.

Practical takeaway

For clinics, reliability assurance is a workflow issue. Clear records, consistent procedures, and defined accountability reduce both regulatory risk and the operational cost of answering questions later.